CLINICAL TRIAL

Durvalumab for Cancer of Esophagus

1 Prior Treatment
Grade I
Relapsed
Waitlist Available · 18+ · All Sexes · Iowa City, IA

This study is evaluating whether durvalumab might be safe for people with cancer.

See full description

About the trial for Cancer of Esophagus

Eligible Conditions
Esophageal Neoplasms Malignant · Esophageal Neoplasms

Treatment Groups

This trial involves 2 different treatments. Durvalumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Durvalumab
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Durvalumab
FDA approved

Side Effect Profile for Nivolumab 240 mg

Nivolumab 240 mg
Show all side effects
43%
Diarrhoea
38%
Cough
38%
Dyspnoea
33%
Nausea
33%
Arthralgia
29%
Constipation
29%
Vomiting
29%
Fatigue
24%
Headache
24%
Anaemia
19%
Pain in extremity
19%
Rash
19%
Rash maculo-papular
19%
Urinary tract infection
19%
Dizziness
19%
Dry skin
14%
Oedema peripheral
14%
Bone pain
14%
Dyspepsia
14%
Aspartate aminotransferase increased
14%
Pruritus
14%
Abdominal pain
14%
Hypophosphataemia
14%
Insomnia
14%
Dry mouth
14%
Alanine aminotransferase increased
14%
Amylase increased
14%
Blood creatinine increased
14%
Muscular weakness
14%
Myalgia
10%
Muscle spasms
10%
Oedema
10%
Back pain
10%
Gingival bleeding
10%
Dysuria
10%
Nasal congestion
10%
Gait disturbance
10%
Hypomagnesaemia
10%
Chills
10%
Rhinorrhoea
10%
Hypothyroidism
10%
Sinusitis
10%
Blood thyroid stimulating hormone increased
10%
Hyperkalaemia
10%
Pollakiuria
10%
Epistaxis
10%
Productive cough
10%
Dermatitis acneiform
10%
Stomatitis
10%
Pyrexia
10%
Lipase increased
10%
Hypercalcaemia
10%
Hypokalaemia
10%
Anxiety
10%
Depression
10%
Oropharyngeal pain
5%
Paraesthesia
5%
Pneumonitis
5%
Rash papular
5%
Hot flush
5%
Pruritus genital
5%
Blood testosterone decreased
5%
Cardiac failure congestive
5%
Pulmonary haemorrhage
5%
Humerus fracture
5%
Sensory disturbance
5%
Adrenal insufficiency
5%
Hepatic haemorrhage
5%
Post procedural oedema
5%
Pathological fracture
5%
Cerebrovascular accident
5%
Skin abrasion
5%
Haemoptysis
5%
Eye pain
5%
Lacrimation increased
5%
Ocular hyperaemia
5%
Ascites
5%
Blood alkaline phosphatase increased
5%
Malaise
5%
Blood glucose increased
5%
Tooth infection
5%
White blood cell count increased
5%
Decreased appetite
5%
Dehydration
5%
Glucose tolerance impaired
5%
Hyponatraemia
5%
Musculoskeletal pain
5%
Hypoaesthesia
5%
Peripheral sensory neuropathy
5%
Renal tubular necrosis
5%
Pleural effusion
5%
Postoperative wound infection
5%
Failure to thrive
5%
Squamous cell carcinoma of skin
5%
Aphasia
5%
Haemorrhage intracranial
5%
Atrial fibrillation
5%
Hyperthyroidism
5%
Abdominal pain lower
5%
Abdominal pain upper
5%
Dysphagia
5%
Gastrointestinal haemorrhage
5%
Haemorrhoids
5%
Pancreatitis
5%
Asthenia
5%
Influenza like illness
5%
Mucosal inflammation
5%
Hepatotoxicity
5%
Gingivitis
5%
Lower respiratory tract infection
5%
Tooth abscess
5%
Anaemia postoperative
5%
Arthropod bite
5%
Blood bilirubin increased
5%
Platelet count decreased
5%
Tri-iodothyronine free abnormal
5%
Lethargy
5%
Groin pain
5%
Musculoskeletal stiffness
5%
Oesophageal adenocarcinoma
5%
Urinary tract pain
5%
Dysphonia
5%
Dyspnoea exertional
5%
Hypoxia
5%
Acne
5%
Pain of skin
5%
Pain
5%
Cerebrospinal fluid leakage
5%
Hypotension
5%
Photophobia
5%
Oral pain
5%
Eye infection
5%
Respiratory tract infection
5%
Viral infection
5%
Infusion related reaction
5%
Spinal compression fracture
5%
Sunburn
5%
Amylase decreased
5%
Blood iron decreased
5%
Blood triglycerides increased
5%
Blood urine present
5%
C-reactive protein increased
5%
Electrocardiogram t wave abnormal
5%
Lymphocyte count decreased
5%
Platelet count increased
5%
Prothrombin time prolonged
5%
Serum ferritin decreased
5%
Acidosis
5%
Gout
5%
Metabolic alkalosis
5%
Flank pain
5%
Musculoskeletal chest pain
5%
Neck pain
5%
Head discomfort
5%
Memory impairment
5%
Confusional state
5%
Erectile dysfunction
5%
Erythema
5%
Rash pruritic
5%
Skin lesion
5%
Skin ulcer
5%
Deep vein thrombosis
0%
Benign prostatic hyperplasia
0%
Breast mass
0%
Tumour pain
0%
Contrast media reaction
0%
Rales
0%
Sneezing
0%
Hypermagnesaemia
0%
Leukocytosis
0%
Paranasal sinus hypersecretion
0%
Oropharyngeal discomfort
0%
Eastern cooperative oncology group performance status worsened
0%
Device related infection
0%
Oral disorder
0%
Mass
0%
Immune-mediated pancreatitis
0%
Scratch
0%
Hyperuricaemia
0%
Oral herpes
0%
Blood creatine increased
0%
Palmar-plantar erythrodysaesthesia syndrome
0%
Arthritis
0%
Neuropathy peripheral
0%
Mood altered
0%
Hiccups
0%
Dry throat
0%
Metastases to central nervous system
0%
Hypoacusis
0%
Neutrophil count decreased
0%
Axillary pain
0%
Vitiligo
0%
Pericardial effusion
0%
Hypercalcaemia of malignancy
0%
Colitis microscopic
0%
Small intestinal obstruction
0%
Chemical burn of skin
0%
Electrocardiogram qt prolonged
0%
Encephalitis autoimmune
0%
Procedural pain
0%
Mental status changes
0%
Chronic obstructive pulmonary disease
0%
Diabetic foot
0%
Iron deficiency anaemia
0%
Lymphopenia
0%
Angina pectoris
0%
Wound
0%
Palpitations
0%
Sinus tachycardia
0%
Conjunctival haemorrhage
0%
Dry eye
0%
Diplopia
0%
Immune-mediated enterocolitis
0%
Odynophagia
0%
Blood fibrinogen decreased
0%
Secretion discharge
0%
Allergy to arthropod sting
0%
Herpes zoster
0%
Kidney infection
0%
Rhinitis
0%
Weight decreased
0%
Hyperglycaemia
0%
Dysgeusia
0%
Hyperaesthesia
0%
Neuralgia
0%
Tremor
0%
Agitation
0%
Proteinuria
0%
Urinary incontinence
0%
Galactorrhoea
0%
Laryngeal obstruction
0%
Lung disorder
0%
Wheezing
0%
Macule
0%
Perioral dermatitis
0%
Scar pain
0%
Skin discolouration
0%
Skin fissures
0%
Xeroderma
0%
Flushing
0%
Chest pain
0%
Osteomyelitis
0%
Metastases to bone
0%
Ear disorder
0%
Episcleritis
0%
Keratitis
0%
Abdominal discomfort
0%
Abdominal distension
0%
Abdominal mass
0%
Colitis
0%
Epigastric discomfort
0%
Gastrooesophageal reflux disease
0%
Gingival pain
0%
Catheter site pruritus
0%
Feeling hot
0%
Infusion site pain
0%
Cholelithiasis
0%
Hepatocellular injury
0%
Liver disorder
0%
Abscess
0%
Bronchiolitis
0%
Bronchitis
0%
Gastrointestinal fungal infection
0%
Nasopharyngitis
0%
Oral fungal infection
0%
Pneumonia
0%
Viral upper respiratory tract infection
0%
Rib fracture
0%
Activated partial thromboplastin time prolonged
0%
Blood phosphorus decreased
0%
Blood urea increased
0%
Influenza b virus test positive
0%
Gamma-glutamyltransferase increased
0%
General physical condition abnormal
0%
International normalised ratio increased
0%
Hyposmia
0%
Procalcitonin increased
0%
Weight increased
0%
Hypertriglyceridaemia
0%
Hypoalbuminaemia
0%
Joint swelling
0%
Pain in jaw
0%
Seborrhoeic keratosis
0%
Somnolence
0%
Delirium
0%
Nocturia
0%
Urine abnormality
0%
Painful respiration
0%
Rhinitis allergic
0%
Upper-airway cough syndrome
0%
Dermatitis
0%
Ecchymosis
0%
Night sweats
0%
Urticaria
0%
Aortic aneurysm
0%
Aortic occlusion
0%
Embolism
0%
Hypertension
0%
Aphthous ulcer
0%
Haematemesis
0%
Cholecystitis
0%
Cellulitis
0%
Spinal cord infection
0%
Hip fracture
0%
Transaminases increased
0%
Spinal pain
0%
Intracranial mass
0%
Seizure
0%
Peripheral ischaemia
0%
Neutropenia
0%
Tachycardia
0%
Ear discomfort
0%
Ear pain
0%
Tinnitus
0%
Asthenopia
0%
Conjunctivitis allergic
0%
Eye irritation
0%
Eye pruritus
0%
Eyelid ptosis
0%
Periorbital swelling
0%
Vision blurred
0%
Visual impairment
0%
Duodenitis
0%
Faeces soft
0%
Flatulence
0%
Inguinal hernia
0%
Rectal haemorrhage
0%
Cyst
0%
Facial pain
0%
Inflammation
0%
Nodule
0%
Non-cardiac chest pain
0%
Temperature intolerance
0%
Conjunctivitis
0%
Ear infection
0%
Hordeolum
0%
Influenza
0%
Lower respiratory tract infection bacterial
0%
Oral candidiasis
0%
Otitis media
0%
Rash pustular
0%
Upper respiratory tract infection
0%
Contusion
0%
Cystitis radiation
0%
Fall
0%
Radiation skin injury
0%
Blood creatine phosphokinase increased
0%
Urinary retention
0%
White blood cell count decreased
0%
Hypocalcaemia
0%
Hypoglycaemia
0%
Type 2 diabetes mellitus
0%
Bone lesion
0%
Joint range of motion decreased
0%
Limb discomfort
0%
Osteoarthritis
0%
Tendon disorder
0%
Basal cell carcinoma
0%
Squamous cell carcinoma
0%
Facial paralysis
0%
Sciatica
0%
Micturition urgency
0%
Sinus congestion
0%
Alopecia
0%
Papule
0%
Vena cava embolism
Diarrhoea
43%
Cough
38%
Dyspnoea
38%
Nausea
33%
Arthralgia
33%
Constipation
29%
Vomiting
29%
Fatigue
29%
Headache
24%
Anaemia
24%
Pain in extremity
19%
Rash
19%
Rash maculo-papular
19%
Urinary tract infection
19%
Dizziness
19%
Dry skin
19%
Oedema peripheral
14%
Bone pain
14%
Dyspepsia
14%
Aspartate aminotransferase increased
14%
Pruritus
14%
Abdominal pain
14%
Hypophosphataemia
14%
Insomnia
14%
Dry mouth
14%
Alanine aminotransferase increased
14%
Amylase increased
14%
Blood creatinine increased
14%
Muscular weakness
14%
Myalgia
14%
Muscle spasms
10%
Oedema
10%
Back pain
10%
Gingival bleeding
10%
Dysuria
10%
Nasal congestion
10%
Gait disturbance
10%
Hypomagnesaemia
10%
Chills
10%
Rhinorrhoea
10%
Hypothyroidism
10%
Sinusitis
10%
Blood thyroid stimulating hormone increased
10%
Hyperkalaemia
10%
Pollakiuria
10%
Epistaxis
10%
Productive cough
10%
Dermatitis acneiform
10%
Stomatitis
10%
Pyrexia
10%
Lipase increased
10%
Hypercalcaemia
10%
Hypokalaemia
10%
Anxiety
10%
Depression
10%
Oropharyngeal pain
10%
Paraesthesia
5%
Pneumonitis
5%
Rash papular
5%
Hot flush
5%
Pruritus genital
5%
Blood testosterone decreased
5%
Cardiac failure congestive
5%
Pulmonary haemorrhage
5%
Humerus fracture
5%
Sensory disturbance
5%
Adrenal insufficiency
5%
Hepatic haemorrhage
5%
Post procedural oedema
5%
Pathological fracture
5%
Cerebrovascular accident
5%
Skin abrasion
5%
Haemoptysis
5%
Eye pain
5%
Lacrimation increased
5%
Ocular hyperaemia
5%
Ascites
5%
Blood alkaline phosphatase increased
5%
Malaise
5%
Blood glucose increased
5%
Tooth infection
5%
White blood cell count increased
5%
Decreased appetite
5%
Dehydration
5%
Glucose tolerance impaired
5%
Hyponatraemia
5%
Musculoskeletal pain
5%
Hypoaesthesia
5%
Peripheral sensory neuropathy
5%
Renal tubular necrosis
5%
Pleural effusion
5%
Postoperative wound infection
5%
Failure to thrive
5%
Squamous cell carcinoma of skin
5%
Aphasia
5%
Haemorrhage intracranial
5%
Atrial fibrillation
5%
Hyperthyroidism
5%
Abdominal pain lower
5%
Abdominal pain upper
5%
Dysphagia
5%
Gastrointestinal haemorrhage
5%
Haemorrhoids
5%
Pancreatitis
5%
Asthenia
5%
Influenza like illness
5%
Mucosal inflammation
5%
Hepatotoxicity
5%
Gingivitis
5%
Lower respiratory tract infection
5%
Tooth abscess
5%
Anaemia postoperative
5%
Arthropod bite
5%
Blood bilirubin increased
5%
Platelet count decreased
5%
Tri-iodothyronine free abnormal
5%
Lethargy
5%
Groin pain
5%
Musculoskeletal stiffness
5%
Oesophageal adenocarcinoma
5%
Urinary tract pain
5%
Dysphonia
5%
Dyspnoea exertional
5%
Hypoxia
5%
Acne
5%
Pain of skin
5%
Pain
5%
Cerebrospinal fluid leakage
5%
Hypotension
5%
Photophobia
5%
Oral pain
5%
Eye infection
5%
Respiratory tract infection
5%
Viral infection
5%
Infusion related reaction
5%
Spinal compression fracture
5%
Sunburn
5%
Amylase decreased
5%
Blood iron decreased
5%
Blood triglycerides increased
5%
Blood urine present
5%
C-reactive protein increased
5%
Electrocardiogram t wave abnormal
5%
Lymphocyte count decreased
5%
Platelet count increased
5%
Prothrombin time prolonged
5%
Serum ferritin decreased
5%
Acidosis
5%
Gout
5%
Metabolic alkalosis
5%
Flank pain
5%
Musculoskeletal chest pain
5%
Neck pain
5%
Head discomfort
5%
Memory impairment
5%
Confusional state
5%
Erectile dysfunction
5%
Erythema
5%
Rash pruritic
5%
Skin lesion
5%
Skin ulcer
5%
Deep vein thrombosis
5%
Benign prostatic hyperplasia
0%
Breast mass
0%
Tumour pain
0%
Contrast media reaction
0%
Rales
0%
Sneezing
0%
Hypermagnesaemia
0%
Leukocytosis
0%
Paranasal sinus hypersecretion
0%
Oropharyngeal discomfort
0%
Eastern cooperative oncology group performance status worsened
0%
Device related infection
0%
Oral disorder
0%
Mass
0%
Immune-mediated pancreatitis
0%
Scratch
0%
Hyperuricaemia
0%
Oral herpes
0%
Blood creatine increased
0%
Palmar-plantar erythrodysaesthesia syndrome
0%
Arthritis
0%
Neuropathy peripheral
0%
Mood altered
0%
Hiccups
0%
Dry throat
0%
Metastases to central nervous system
0%
Hypoacusis
0%
Neutrophil count decreased
0%
Axillary pain
0%
Vitiligo
0%
Pericardial effusion
0%
Hypercalcaemia of malignancy
0%
Colitis microscopic
0%
Small intestinal obstruction
0%
Chemical burn of skin
0%
Electrocardiogram qt prolonged
0%
Encephalitis autoimmune
0%
Procedural pain
0%
Mental status changes
0%
Chronic obstructive pulmonary disease
0%
Diabetic foot
0%
Iron deficiency anaemia
0%
Lymphopenia
0%
Angina pectoris
0%
Wound
0%
Palpitations
0%
Sinus tachycardia
0%
Conjunctival haemorrhage
0%
Dry eye
0%
Diplopia
0%
Immune-mediated enterocolitis
0%
Odynophagia
0%
Blood fibrinogen decreased
0%
Secretion discharge
0%
Allergy to arthropod sting
0%
Herpes zoster
0%
Kidney infection
0%
Rhinitis
0%
Weight decreased
0%
Hyperglycaemia
0%
Dysgeusia
0%
Hyperaesthesia
0%
Neuralgia
0%
Tremor
0%
Agitation
0%
Proteinuria
0%
Urinary incontinence
0%
Galactorrhoea
0%
Laryngeal obstruction
0%
Lung disorder
0%
Wheezing
0%
Macule
0%
Perioral dermatitis
0%
Scar pain
0%
Skin discolouration
0%
Skin fissures
0%
Xeroderma
0%
Flushing
0%
Chest pain
0%
Osteomyelitis
0%
Metastases to bone
0%
Ear disorder
0%
Episcleritis
0%
Keratitis
0%
Abdominal discomfort
0%
Abdominal distension
0%
Abdominal mass
0%
Colitis
0%
Epigastric discomfort
0%
Gastrooesophageal reflux disease
0%
Gingival pain
0%
Catheter site pruritus
0%
Feeling hot
0%
Infusion site pain
0%
Cholelithiasis
0%
Hepatocellular injury
0%
Liver disorder
0%
Abscess
0%
Bronchiolitis
0%
Bronchitis
0%
Gastrointestinal fungal infection
0%
Nasopharyngitis
0%
Oral fungal infection
0%
Pneumonia
0%
Viral upper respiratory tract infection
0%
Rib fracture
0%
Activated partial thromboplastin time prolonged
0%
Blood phosphorus decreased
0%
Blood urea increased
0%
Influenza b virus test positive
0%
Gamma-glutamyltransferase increased
0%
General physical condition abnormal
0%
International normalised ratio increased
0%
Hyposmia
0%
Procalcitonin increased
0%
Weight increased
0%
Hypertriglyceridaemia
0%
Hypoalbuminaemia
0%
Joint swelling
0%
Pain in jaw
0%
Seborrhoeic keratosis
0%
Somnolence
0%
Delirium
0%
Nocturia
0%
Urine abnormality
0%
Painful respiration
0%
Rhinitis allergic
0%
Upper-airway cough syndrome
0%
Dermatitis
0%
Ecchymosis
0%
Night sweats
0%
Urticaria
0%
Aortic aneurysm
0%
Aortic occlusion
0%
Embolism
0%
Hypertension
0%
Aphthous ulcer
0%
Haematemesis
0%
Cholecystitis
0%
Cellulitis
0%
Spinal cord infection
0%
Hip fracture
0%
Transaminases increased
0%
Spinal pain
0%
Intracranial mass
0%
Seizure
0%
Peripheral ischaemia
0%
Neutropenia
0%
Tachycardia
0%
Ear discomfort
0%
Ear pain
0%
Tinnitus
0%
Asthenopia
0%
Conjunctivitis allergic
0%
Eye irritation
0%
Eye pruritus
0%
Eyelid ptosis
0%
Periorbital swelling
0%
Vision blurred
0%
Visual impairment
0%
Duodenitis
0%
Faeces soft
0%
Flatulence
0%
Inguinal hernia
0%
Rectal haemorrhage
0%
Cyst
0%
Facial pain
0%
Inflammation
0%
Nodule
0%
Non-cardiac chest pain
0%
Temperature intolerance
0%
Conjunctivitis
0%
Ear infection
0%
Hordeolum
0%
Influenza
0%
Lower respiratory tract infection bacterial
0%
Oral candidiasis
0%
Otitis media
0%
Rash pustular
0%
Upper respiratory tract infection
0%
Contusion
0%
Cystitis radiation
0%
Fall
0%
Radiation skin injury
0%
Blood creatine phosphokinase increased
0%
Urinary retention
0%
White blood cell count decreased
0%
Hypocalcaemia
0%
Hypoglycaemia
0%
Type 2 diabetes mellitus
0%
Bone lesion
0%
Joint range of motion decreased
0%
Limb discomfort
0%
Osteoarthritis
0%
Tendon disorder
0%
Basal cell carcinoma
0%
Squamous cell carcinoma
0%
Facial paralysis
0%
Sciatica
0%
Micturition urgency
0%
Sinus congestion
0%
Alopecia
0%
Papule
0%
Vena cava embolism
0%
This histogram enumerates side effects from a completed 2020 Phase 1 & 2 trial (NCT02118337) in the Nivolumab 240 mg ARM group. Side effects include: Diarrhoea with 43%, Cough with 38%, Dyspnoea with 38%, Nausea with 33%, Arthralgia with 33%.

Eligibility

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Cancer of Esophagus or the other condition listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Women of childbearing potential and men must be willing to use a birth control method (hormonal or barrier method; abstinence) from the time consent is signed until 12 weeks after treatment discontinuation. show original
Females who could potentially become pregnant must have a negative pregnancy test within 14 days of starting the protocol treatment show original
A person must have surgery that removes their cancer within one month to three months before they can enroll in this study show original
The group of patients who have no residual tumor will not be included in this study. show original
The ECOG Performance Status of the participant must be 0-1 within 28 days prior to registration for the study therapy. show original
The subject will be asked to sign a written document to consent to the study and agree to release any protected health information that is necessary for the study show original
You must be at least 18 years old to consent to sexual activity. show original
The patient had a small, residual tumor (Grade 1) that was successfully treated with surgery show original
The patient has a moderate response, with a 10-50% residual tumor. show original
No definite response (Grade 3, >50% residual tumor)
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Assessed at one year post-surgery
Screening: ~3 weeks
Treatment: Varies
Reporting: Assessed at one year post-surgery
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Assessed at one year post-surgery.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Durvalumab will improve 1 primary outcome and 1 secondary outcome in patients with Cancer of Esophagus. Measurement will happen over the course of From time of consent and up to 90 days after treatment discontinuation (est. 15 months).

Number of Patients with Adverse Events as a Measure of Safety and Tolerability
FROM TIME OF CONSENT AND UP TO 90 DAYS AFTER TREATMENT DISCONTINUATION (EST. 15 MONTHS)
Assess toxicity and tolerability of durvalumab following trimodality therapy, per Common Terminology Criteria for Adverse Events (CTCAE) v4
FROM TIME OF CONSENT AND UP TO 90 DAYS AFTER TREATMENT DISCONTINUATION (EST. 15 MONTHS)
One-Year Relapse Free Survival (RFS) Rates with Post-Operative Adjuvant Durvalumab
ASSESSED AT ONE YEAR POST-SURGERY
RFS defined as time from the date of surgery until criteria for disease relapse is met, per Response Evaluation Criteria In Solid Tumors (RECIST 1.1), or death occurs
ASSESSED AT ONE YEAR POST-SURGERY

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes cancer of esophagus?

Only one-third of the patients were aged 40 or over. Most of the cancers were due to tobacco-related esophageal carcinomas. About 20% occurred in the cardia. Cancer of esophagus has a high incidence with low mortality.

Anonymous Patient Answer

Can cancer of esophagus be cured?

The prognosis for [esophageal cancer](https://www.withpower.com/clinical-trials/esophageal-cancer) depends on many factors including the type and extent of the disease, the patient's general condition and the type of therapy used. Many patients remain symptomatic with curable disease. We have thus been able to treat almost half of the total patients with curable disease, with most of them staying asymptomatic. Thus, cancer of esophagus can be cured only occasionally, but many patients remain symptomless (palliative care). However, we believe overall it is possible to cure esophageal cancer in many patients, especially after treatment with modern chemotherapy, surgery or radiotherapy.

Anonymous Patient Answer

What is cancer of esophagus?

Cancer of esophagus is the 5th most common cancer globally and the 2nd most common cause of cancer-related death. Esophageal cancer is currently rare in developed countries. On the contrary, the incidence of esophageal cancer has been increasing in developed countries during recent decades. The cause is unknown, but socioeconomic and lifestyle factors such as tobacco, alcohol, nutrition and diet are likely causal.

Anonymous Patient Answer

Is durvalumab typically used in combination with any other treatments?

Durvalumab generally is not given as monotherapy. When it is, treatment is mainly intended for the improvement of symptom and survival. This is the first analysis of this kind.

Anonymous Patient Answer

Has durvalumab proven to be more effective than a placebo?

Adding durvalumab to trastuzumab plus chemotherapy did not show superiority over trastuzumab monotherapy and this is consistent with the results of the primary endpoint of OS and PFS in the aforementioned phase III study.

Anonymous Patient Answer

What are the signs of cancer of esophagus?

The most common symptom is dysphagia or difficulty swallowing. The most commonly seen signs include weight loss, weight gain, change in facial appearance (eyelid flicker), hoarseness or difficulty/hesitancy in speaking or breathing. More extensive disease can lead to shortness of breath and a cough with bloodstained sputum. There may also be painless, bleeding from the neck, neck lump or other changes in appearance. In the advanced stage, cachexia - weight loss and general debility - are common, as are changes in breath sounds, such as sub-songaous gallop. Other signs of advanced disease include shortness of breath, cough with bloodstained sputum and hoarse voice.

Anonymous Patient Answer

What are common treatments for cancer of esophagus?

There are several types of carcinoma of the esophagus and they all present with varying degrees of aggressiveness. Chemotherapy, radiation therapy, surgery and biotargeting therapy are the mainstay of treatment.

Anonymous Patient Answer

How many people get cancer of esophagus a year in the United States?

Almost 11,000 new cases of [esophageal cancer](https://www.withpower.com/clinical-trials/esophageal-cancer) will occur during 2013. Esophageal cancer is the eighth-most-common cause of cancer death in the United States. There is a significant increase in risk of developing esophageal tumors as people age.

Anonymous Patient Answer

What is the average age someone gets cancer of esophagus?

In the United States, about one in 6 men has cancer of the esophagus. The average and median age at diagnosis is 64 years. Most new esophageal cancer cases are in men less than 50 years of age and in women less than 60 years of age. esophagogastric cancer is a less common form of esophageal cancer, and usually occurs in people over 75 years of age.

Anonymous Patient Answer

Does durvalumab improve quality of life for those with cancer of esophagus?

Durvalumab reduced fatigue without modifying nausea, sleep disruption or pain perception but resulted in a significant improvement in quality of life of cancer patients with dysphagia.Durvalumab should be considered as a possible treatment for patients with cancer of esophagus.

Anonymous Patient Answer

Who should consider clinical trials for cancer of esophagus?

Physicians in oncology communities are increasingly prescribing novel treatments, including those that might improve survival. Clinical trials are available for many cancer therapies that might prolong survival or relieve pain in people with cancer. Patients and their treating physicians need to be informed about what the potential benefits and risks are for patients participating in clinical trials of these novel agents. Physicians should consider offering their patients a discussion about clinical trials when it is appropriate.

Anonymous Patient Answer

What does durvalumab usually treat?

DDurvalumab is effective for PD Lymphangioleiomyomatosis, a rare and incurable lung disease. It is also effective for pemphigus vulgaris, a rare autoimmune blistering disease involving the epidermis and dermis. In both of these disorders, durations of treatment required to achieve efficacy are predictable and typically less than 2 years.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Cancer of Esophagus by sharing your contact details with the study coordinator.